Medicine adaptive pathways to patients (MAPPs): using regulatory innovation to defeat Eroom's law.

@article{Schulthess2014MedicineAP,
  title={Medicine adaptive pathways to patients (MAPPs): using regulatory innovation to defeat Eroom's law.},
  author={Duane Schulthess and Magda Chlebus and Richard Bergstrӧm and Karin Van Baelen},
  journal={Chinese clinical oncology},
  year={2014},
  volume={3 2},
  pages={21}
}
Eroom's Law is, literally, Moore's law in reverse. The pharmaceutical sector invests $50 billion annually in research for new medicines but, "the number of new drugs approved per billion US dollars spent has halved roughly every 9 years since 1950, falling around 80-fold in inflation-adjusted terms". Pharmaceutical companies have invested enormous sums in new molecular entities (NME) in the areas of unmet medical need identified by the World Health Organization (WHO), but the approval rates… CONTINUE READING